Harimoto Tetsuhiro, Danino Tal
Department of Biomedical Engineering, Columbia University, New York, NY, U.S.A.
Data Science Institute, Columbia University, New York, NY, U.S.A.
Emerg Top Life Sci. 2019 Nov 11;3(5):623-629. doi: 10.1042/ETLS20190096.
The engineering of living cells and microbes is ushering in a new era of cancer therapy. Due to recent microbiome studies indicating the prevalence of bacteria within the human body and specifically in tumor tissue, bacteria have generated significant interest as potential targets for cancer therapy. Notably, a multitude of empirical studies over the past decades have demonstrated that administered bacteria home and grow in tumors due to reduced immune surveillance of tumor necrotic cores. Given their specificity for tumors, bacteria present a unique opportunity to be engineered as intelligent delivery vehicles for cancer therapy with synthetic biology techniques. In this review, we discuss the history, current state, and future challenges associated with using bacteria as a cancer therapy.
活细胞和微生物工程正在开启癌症治疗的新时代。由于最近的微生物组研究表明细菌在人体内普遍存在,特别是在肿瘤组织中,细菌作为癌症治疗的潜在靶点引起了极大的关注。值得注意的是,过去几十年的大量实证研究表明,由于肿瘤坏死核心的免疫监视减弱,施用的细菌会在肿瘤中定植并生长。鉴于细菌对肿瘤的特异性,它们为利用合成生物学技术设计成癌症治疗的智能递送载体提供了独特的机会。在这篇综述中,我们讨论了将细菌用作癌症治疗的历史、现状和未来挑战。